Scientific Articles

Clinical Studies

• The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix
  Maciag PC, et al. Vaccine, 2009, 27(30):3975-3983.
• Therapeutic cancer vaccines in cervical cancer: phase I study of Lovaxin-C
  Radulovic S, et al. J Buon. 2009, Suppl 1:S165-168.

Reviews

• Cancer immunotherapy using recombinant Listeria monocytogenes: Transition from bench to clinic
  Singh R and Wallecha A. Hum Vaccine. 2011. 7(5).
• Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy
  Paterson Y, Guirnalda PD, Wood LM. Semin Immunol. 2010 Jun;22(3):183-9.
• Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment
  Shahabi V, et al. Bioeng Bugs. 2010, 1(4):235-239.
• Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics
  Wallecha A, et al. Adv Appl Microbiol. 2009, 66:1-27.
• Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.
  Wood LM, et al. Immunol Res. 2008. 42(1-3):233-245.
• Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy
  Singh R and Paterson Y. Expert Rev Vaccines. 2006, 5(4):541-552.
• What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors
  Hussain SF and Paterson Y. 2005, 54(6):577-586.
• Listeria-based vaccines for cancer treatment
  Paterson Y and Maciag PC. Curr Opin Mol Ther. 2005, 7(5):454-460.
• Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease
  Weiskirch LM and Paterson Y. Immunol Rev. 1997, 158:159-169.
• Recombinant Listeria monocytogenes cancer vaccines
  Paterson Y and Ikonomidis G. Curr Opin Immunol. 1996, 8(5):664-669.

Cancer

Increase cytotoxic T cells that infiltrate the tumor

• The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy
  Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y. Cancer Immunol Immunother. 2011 Nov 6.
• Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human
  Shahabi V, et al. Cancer Gene Ther. 2010.
• Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy
  Wood LM, et al. Cancer Immunol Immunother. 2010.
• Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic mucosal cell-mediated CD4+ and CD8+ T-cell responses after
  oral immunization
  Mustafa W, et al. Viral Immunol. 2009, 22(3):195-204.
• High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action
  Kim SH, et al. Cancer Res. 2009, 69(14):5860-5866.
• An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytgenes anti-angiogenesis cancer vaccine for the
  treatment of primary and metastatic Her-2/neu+ breast tuomors in a mouse model
  Seavey MM, et al. J Immunol. 2009, 182(9):5537-5546.
• A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors
  Seavey MM, et al. Clin Cancer Res. 2009, 15(3):924-932.
• Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy
  Wallecha A, et al. Clin Vaccine Immunol. 2009, 16(1):96-103.
• Development of a Listeria monocytogenes based vaccine against prostate cancer
  Shahabi V, et al. Cancer Immunol Immunother. 2008, 57(9):1301-1313.
• Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors
  Sewell DA, et al. Vaccine. 2008, 26(41):5315-5320.
• Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases
  Kim SH, et al. Br J Cancer. 2008, 99(5):741-749.
• In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria
  monocytogenes-based vaccines
  Singh R and Paterson Y. Cancer Immunol Immunother. 2007, 56(6):927-938.
• Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse
  model of cancer
  Souders NC, et al. Cancer Immun. 2007, 7:2.
• In vivo bactofection: listeria can function as a DNA-cancer vaccine
  Souders NC, et al. DNA Cell Biol. 2006, 25(3):142-151.
• Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in
  the FVB/N mouse
  Singh R, et al. J Immunol. 2005, 175(6):3663-­3673.
• Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7
  Sewell DA, et al. Cancer Res. 2004, 64(24):8821-8825.
• Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine
  Sewell DA, et al. Arch Otolaryngol Head Neck Surg. 2004, 130(1):92-97.
• Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively
  different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16
  Gunn GR, et al. J Immunol. 2001, 167(11):6471-6479.
• The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector
  mechanisms
  Weiskirch LM, et al. Clin Immunol. 2001, 98(3):346-357.
• A recombinant Listeria monocytogenes vaccine expressing a model tumor antigen protects mice against lethal tumour cell challenge and causes
  regression of established tumours
  Pan ZK, et al. Nat Med. 1995, 1(5):471-477.

Reduce suppressive T cells in the tumors

• Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy
  Wallecha A, et al. Clin Vaccine Immunol. 2009, 16(1):96-103.
• Development of a Listeria monocytogenes based vaccine against prostate cancer
  Shahabi V, et al. Cancer Immunol Immunother. 2008, 57(9):1301-1313.
• CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. Hussain SF, et al. J Immunother. 2004, 27(5):339-346.

Alteration of vasculature, stromal effects, and cytokine production

• Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105
  Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M, Paterson Y.
• Effect of a novel DNA vaccine on angiogenesis and tumor growth in vivo
  McKinney KA, et al. Arch Otolaryngol Head Neck Surg. 2010, 136(9):859-864.
• An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine or the
  treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model
  Seavey MM, et al. J Immunol. 2009, 182(9):5537-5546.
• Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy
  Peng X, et al. Cancer Immunol Immunother. 2007, 56(6):797-806.
• The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid
  dendritic cell function
  Peng X, et al. J Immunol. 2004, 172(10):6030-6038.
• Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively
  different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16
  Gunn GR, et al. J Immunol. 2001, 167(11):6471-6479.
• The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine comprises multiple effector
  mechanisms
  Weiskirch LM, et al. Clin Immunol. 2001, 98(3)346-357.
• Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine
  Pan ZK, et al. Cancer Res. 1999, 59(20):5264-5269.

Novel strains, constructs, and techniques

• Effect of a novel DNA vaccine on angiogenesis and tumor growth in vivo
  McKinney KA, et al. Arch Otolaryngol Head Neck Surg. 2010, 136(9):859-864.
• Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy
  Wallecha A, et al. Clin Vaccine Immunol. 2009, 16(1):6-103.
• Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines
  Verch T, et al. Infect Immun. 2004, 72(11):6418-6425.
• Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts
  Peters C and Paterson Y. Vaccine. 2003, 21(11-12):1187-1194.
• Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively
  different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16
  Gunn GR, et al. J Immunol. 2001, 167(11):6471-6479.
• Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine
  Schafer R, et al. J Immunol. 1992, 49(1):53-59.

Studies in transgenic mice/tolerance systems

• Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human
  Shahabi V, et al. Cancer Gene Ther. 2010.
• A novel human Her-2/neu chimerical molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell
  responses and impact the growth and spread of Her-2/neu-positive breast tumors
  Seavey MM, et al. Clin Cancer Res. 2009, 15(3):924-932.
• An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the
  treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model
  Seavey MM, et al. J Immunol. 2009, 182(9):5537-5546.
• Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors
  Sewell DA, et al. Vaccine. 2008, 26(41):5315-5320.
• In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria
  monocytogenes-based vaccines
  Singh R and Paterson Y. Cancer Imunol Immunother. 2007, 56(6):927-938
• Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse
  model of cancer
  Souders NC, et al. Cancer Immun. 2007, 7:2.

Epitope Spreading

• An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the
  treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model
  Seavey MM, et al. J Immunol. 2009, 182(9):5537-5546.
• Anti-Angiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting
  Seavey MM, Paterson Y. Breast Cancer (London). 2009;1:19-30.

Infectious Disease Literature

Infectious Disease

• A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of
  alpha4beta7 integrin and an effector memory phenotype
  Neeson P, et al. Virology. 2006, 354(2):299-315.
• DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression
  of SIV239 viral replication
  Boyer JD, et al. Virology. 2005, 333(1):88-101
• Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens
  Paterson Y and Johnson RS. Expert Rev Vaccines. 2004, 3(4 Suppl):S119-134.
• The induction of HIV Gag-specific CD8+ T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with
  recombinant Listeria monocytogenes HIV Gag
  Peters C, et al. J Immunol. 2003, 170(10):5176-5187
• Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge
  Mata M, et al. Vaccine. 2001, 19(11-12):434-1445.
• Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial
  antigens
  Mata M and Paterson Y. J Immunol. 1999, 163(3):1449-1456.